polycythemia vera
Novartis blood cancer drug given EU nod
March 17, 2015Sales and Marketing Cancer, EU, Jakavi, Novartis, oncology, polycythemia vera, ruxolitinib
Novartis’ blood cancer drug Jakavi has been given the green light in Europe to treat adult patients with polycythemia vera …
Latest content
The evidence bar impacting UK medical cannabis access
November 6, 2026
Addressing the rheumatic disease diagnostic gap in primary care
November 5, 2026
